Physician profile
Patrick A Cambier
NPI 1508828591
$900,660.33
in general payments reported to CMS, 2019-2025
40 companies · $101K in 2025
The $101K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $165K · 2021: $96K · 2022: $187K · 2023: $136K · 2024: $121K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $270K · Consulting Fee: $32K · Travel and Lodging: $29K · Long Term Medical Supply Or Device Loan: $18K · Food and Beverage: $9,682 · Education: $35.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $269,921.75 |
| Consulting Fee | $31,502.25 |
| Travel and Lodging | $29,051.54 |
| Long Term Medical Supply Or Device Loan | $18,305.55 |
| Food and Beverage | $9,681.71 |
| Education | $35.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $330,664.58 | 2019-2025 | Farxiga, Breztri, Brilinta |
| Novo Nordisk INC | $300,535.96 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Merck Sharp & Dohme LLC | $100,988.77 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $77,035.00 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $60,995.72 | 2019-2025 | |
| Angiodynamics, INC. | $22,011.07 | 2020-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Teleflex LLC | $1,210.08 | 2022 | |
| Medtronic, INC. | $1,174.28 | 2021-2025 | Linq II, Micra, Reveal Linq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $837.67 | 2019-2025 | Lifevest |
| Amgen INC. | $668.02 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $547.00 | 2019-2025 | |
| Cardiovascular Systems INC. | $464.70 | 2019-2022 | |
| Abbott Laboratories | $401.27 | 2019-2023 | Femostop |
| Janssen Pharmaceuticals, INC | $319.31 | 2019-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $270.38 | 2024-2025 | Onpattro |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $255.19 | 2019-2025 | Watchman Flx, Jetstream Sc, Eluvia |
| Corindus INC. | $240.16 | 2019 | |
| Astellas Pharma US INC | $229.83 | 2019-2020 | |
| Shockwave Medical, INC | $224.41 | 2020-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $223.18 | 2019-2023 | |
| Amarin Pharma, INC. | $191.81 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.23 | 2019-2025 | Jardiance |
| Abiomed | $163.07 | 2019-2025 | Impella |
| Siemens Medical Solutions USA, INC. | $159.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.13 | 2025 | |
| Lilly USA, LLC | $75.77 | 2023-2024 | Mounjaro, Zepbound |
| Scpharmaceuticals INC. | $67.99 | 2024 | |
| Edwards Lifesciences Corporation | $63.18 | 2019 | |
| Medtronic Vascular, INC. | $57.52 | 2019-2020 | |
| Esperion Therapeutics, INC. | $56.16 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $54.23 | 2023-2024 | Inpefa |
| Inari Medical, INC. | $52.07 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bridgebio Pharma, INC. | $44.34 | 2025 | Attruby |
| United Therapeutics Corporation | $30.88 | 2024 | Tyvaso |
| Biotronik INC. | $27.78 | 2025 | Biomonitor |
| Kestra Medical Technology Services, INC. | $21.10 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, Ltd. | $16.70 | 2021 | |
| Penumbra, INC. | $14.40 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cambier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.